Literature DB >> 3655009

Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis.

M E O'Connell1, W M Awni, M Goodman, O Cass, A P Melikian, G J Wright, G R Matzke.   

Abstract

The disposition of metoclopramide after acute and chronic administration was determined in four diabetic patients with gastroparesis who had a creatinine clearance of 70.8 +/- 10.7 mL/min (mean +/- SD). Single, 10-mg oral and intravenous doses were administered on days 1 and 2, respectively, followed by 10 mg orally every six hours for three weeks. A second, 10-mg intravenous bolus dose was administered on the last morning of chronic therapy. Metoclopramide concentrations were determined by high performance liquid chromatography. The elimination half-life, steady-state volume of distribution, and total body clearance after the initial intravenous dose were 3.9 +/- 1.2 hr, 2.7 +/- 0.3 L/kg, and 0.57 +/- 0.14 L/hr/kg, respectively. The initial bioavailability was 67.7 +/- 12.6%. After three weeks of chronic therapy, no significant differences in total body clearance (0.72 +/- 0.42 L/hr/kg) or bioavailability (77.5 +/- 16.8%) were observed. Thus the pharmacokinetics and bioavailability of metoclopramide were not altered during chronic therapy in these diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3655009     DOI: 10.1002/j.1552-4604.1987.tb03073.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis.

Authors:  F Albani; M R Tamè; R De Palma; M Bernardi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Authors:  P R Gwilt; R R Nahhas; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 5.  Disordered gastric motor function in diabetes mellitus.

Authors:  M Horowitz; R Fraser
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

Review 6.  Diabetic gastroparesis. A critical reappraisal of new treatment strategies.

Authors:  J P Drenth; L G Engels
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.